NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow growth accelerates

Q2 FY2026 financing cash flow of $11.04M rose 222.4% year over year, ahead of the -91.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at -57.8% a year.

Context

  • Financing cash flow amounted to 131.2% of revenue in FY2025, down 1316.3 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +222.4% holds above the trailing-twelve-month pace of -91.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$11.04M-0.2% QoQ
Last fiscal yearDec 2025
$29.52M-95.5% YoY
LTMJun 2026
$41.68M-91.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+222.4%——
1 year-95.5%——
3-year CAGR-57.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
29.52M USD
Year-over-year change
-95.5%
4-year CAGR
-23.2%

Financing Cash Flow vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -91.1% is the lowest of 9, against a peer median of +448.9%.
  • Financing cash flow amounts to 585.3% of revenue for NAMS, versus a peer median of 729.4%.
NAMS Competitors
Financing Cash Flow for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$554.65M USD+115.5%-15.9%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$425.38M USD+1810.7%-15.2%11803.1%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$251.04M USD+567.4%-6.5%19.6%
BIOABioAge Labs, Inc.LTM Mar 2026$136.68M USD-35.4%+66.2%1325.0%
VKTXViking Therapeutics, Inc.LTM Jun 2026$111.25M USD+2441.0%+163.8%—
SEPNSepterna, Inc.LTM Sep 2026$80.93M USD-73.5%-61.7%84.1%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$41.68M USD-91.1%-57.8%585.3%
ATHEAlterity Therapeutics LimitedFY2025A$39.67M AUD+330.4%+34.5%729.4%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$35.74M USD+16725.1%——
Peer median (excluding NAMS) —+448.9%-6.5%729.4%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Depreciation & Amortization5K9K49K113K220K
Deferred Income Tax00000
Stock-Based Compensation1.24M4.12M24.57M33.62M59.43M
Change in Working Capital4.47M10.37M5.87M(32.67M)(7.94M)
Accounts Receivables0(4.18M)4.03M0(13.28M)
Inventory00000
Accounts Payables6.56M4.81M5.07M(12.95M)4.91M
Other Working Capital(2.09M)9.75M(3.23M)(19.73M)427K
Other Non-Cash Items6.55M18.8M5.23M81.98M4.34M
Operating Cash Flow(29.51M)10.67M(141.22M)(158.56M)(147.78M)
Capital Expenditures(24K)(221K)(24K)(672K)(246K)
Acquisitions (Net)00000
Purchases of Investments000(62.18M)(296.73M)
Sales of Investments0000122.06M
Other Investing Activities00000
Investing Cash Flow(24K)(221K)(24K)(62.85M)(174.92M)
Debt Repayment0747K000
Common Stock Issued84.7M396.95M8.91M645.51M29.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(5.79M)014M0
Financing Cash Flow84.7M391.91M8.91M659.51M29.52M
Effect of Forex Changes(4.68M)5.25M5.05M(6.8M)12.76M
Net Change in Cash50.49M407.6M(127.28M)431.29M(280.42M)
Free Cash Flow(29.54M)10.44M(141.24M)(159.24M)(148.03M)

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.